Page last updated: 2024-09-03

valdecoxib and Cardiovascular Diseases

valdecoxib has been researched along with Cardiovascular Diseases in 29 studies

Research

Studies (29)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	29 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Camu, F; Cheung, R; Joshi, GP; Pan, S; Schug, SA	1
Simon, LS; White, WB	1
Fitzgerald, GA	1
Lenzer, J	1
Griffin, MR; Ray, WA; Stein, CM	1
Topol, EJ	1
FitzGerald, GA; Furberg, CD; Psaty, BM	1
Furberg, CD; Psaty, BM	1
Boyce, SW; Brown, MT; Hoeft, A; Langford, RM; Nussmeier, NA; Parlow, JL; Verburg, KM; Whelton, AA	1
Drazen, JM	1
Couzin, J	1
Okie, S	1
Cotter, J; Wooltorton, E	1
Young, D	1
Bolten, WW; Reiter, S	1
Albini, A; Noonan, DM	1
Lang, L	1
Cohen, JS	1
Barnett, EM; Bobadilla, RV; Randels, CL	1
Aldington, S; Beasley, R; Shirtcliffe, P; Weatherall, M	1
Dogné, JM; Hanson, J; Pratico, D; Supuran, C	1
Deray, G; Montalescot, G; Sibilia, J	1
Deray, G; Héloire, F; Valat, JP	1
Jugdutt, BI	1
Tabrizchi, R	1
Salzberg, DJ; Weir, MR	1
Capone, ML; Di Francesco, L; Patrignani, P; Petrelli, M; Tacconelli, S	1

Reviews

9 review(s) available for valdecoxib and Cardiovascular Diseases

Article	Year
Cardiovascular safety of the cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: an analysis of integrated data. Anesthesia and analgesia, 2009, Volume: 108, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Female; Humans; Incidence; Isoxazoles; Male; Middle Aged; Pain, Postoperative; Postoperative Care; Risk Assessment; Risk Factors; Sulfonamides; Thromboembolism; Young Adult	2009
COX-2 selective inhibitors and heart health. Postgraduate medicine, 2005, Volume: 117, Issue:1 Suppl Topics: Adult; Cardiovascular Diseases; Celecoxib; Child; Cyclooxygenase 2 Inhibitors; Humans; Hypertension; Isoxazoles; Lactones; Meta-Analysis as Topic; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones	2005
COX-2 inhibitors and the heart: putting risk in perspective. Advance for nurse practitioners, 2005, Volume: 13, Issue:11 Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Humans; Isoxazoles; Lactones; Patient Selection; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Stomach Ulcer; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
Increased risk of cardiovascular events with parecoxib/valdecoxib: a systematic review and meta-analysis. The New Zealand medical journal, 2005, Nov-25, Volume: 118, Issue:1226 Topics: Cardiac Surgical Procedures; Cardiovascular Diseases; Cerebrovascular Disorders; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Myocardial Infarction; Odds Ratio; Outcome and Process Assessment, Health Care; Pain, Postoperative; Risk Factors; Sulfonamides; Survival Analysis	2005
Coxibs and cardiovascular side-effects: from light to shadow. Current pharmaceutical design, 2006, Volume: 12, Issue:8 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Epoprostenol; Humans; Isoxazoles; Lactones; Pyrazoles; Structure-Activity Relationship; Sulfonamides; Sulfones; Thromboxane A2	2006
[What do we know about the cardiovascular toxicity of the NSAIDs?]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Follow-Up Studies; Humans; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors	2006
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Edema; Heart Failure; Humans; Hypertension; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Odds Ratio; Placebos; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors	2006
COX-2 inhibitors and cardiovascular risk. Sub-cellular biochemistry, 2007, Volume: 42 Topics: Blood Pressure; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Humans; Isoxazoles; Lactones; Lysine; Risk Factors; Sulfonamides; Sulfones; Water-Electrolyte Balance	2007
Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs. Expert opinion on drug safety, 2008, Volume: 7, Issue:1 Topics: Animals; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Isoxazoles; Sulfonamides	2008

Trials

1 trial(s) available for valdecoxib and Cardiovascular Diseases

Article	Year
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. The New England journal of medicine, 2005, Mar-17, Volume: 352, Issue:11 Topics: Administration, Oral; Adult; Aged; Cardiovascular Diseases; Coronary Artery Bypass; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Humans; Infusions, Intravenous; Isoxazoles; Male; Middle Aged; Pain, Postoperative; Sulfonamides	2005

Article

Year

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.

The New England journal of medicine, 2005, Mar-17, Volume: 352, Issue:11

Topics: Administration, Oral; Adult; Aged; Cardiovascular Diseases; Coronary Artery Bypass; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Humans; Infusions, Intravenous; Isoxazoles; Male; Middle Aged; Pain, Postoperative; Sulfonamides

2005

Other Studies

19 other study(ies) available for valdecoxib and Cardiovascular Diseases

Article	Year
Coxibs and cardiovascular disease. The New England journal of medicine, 2004, Oct-21, Volume: 351, Issue:17 Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Epoprostenol; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Naproxen; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk; Sulfonamides; Sulfones; Thromboxane A2; United States; United States Food and Drug Administration	2004
Pfizer criticised over delay in admitting drug's problems. BMJ (Clinical research ed.), 2004, Oct-23, Volume: 329, Issue:7472 Topics: Cardiovascular Diseases; Drug Industry; Humans; Isoxazoles; Sulfonamides	2004
Cardiovascular toxicity of valdecoxib. The New England journal of medicine, 2004, Dec-23, Volume: 351, Issue:26 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Contraindications; Cyclooxygenase Inhibitors; Drug Labeling; Humans; Isoxazoles; Sulfonamides; United States	2004
Arthritis medicines and cardiovascular events--"house of coxibs". JAMA, 2005, Jan-19, Volume: 293, Issue:3 Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Approval; Humans; Isoxazoles; Pyrazoles; Sulfonamides; United States; United States Food and Drug Administration	2005
Parecoxib, valdecoxib, and cardiovascular risk. Circulation, 2005, Jan-25, Volume: 111, Issue:3 Topics: Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Membrane Proteins; Meta-Analysis as Topic; Prodrugs; Product Surveillance, Postmarketing; Prostaglandin-Endoperoxide Synthases; Randomized Controlled Trials as Topic; Risk Assessment; Sulfonamides	2005
COX-2 inhibitors--lessons in drug safety. The New England journal of medicine, 2005, Mar-17, Volume: 352, Issue:11 Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Gastrointestinal Hemorrhage; Humans; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Publishing; Pyrazoles; Randomized Controlled Trials as Topic; Research Design; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
COX-2 inhibitors--a lesson in unexpected problems. The New England journal of medicine, 2005, Mar-17, Volume: 352, Issue:11 Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Gastrointestinal Hemorrhage; Humans; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2005
Drug safety. FDA panel urges caution on many anti-inflammatory drugs. Science (New York, N.Y.), 2005, Feb-25, Volume: 307, Issue:5713 Topics: Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Drug Labeling; Humans; Isoxazoles; Lactones; Pyrazoles; Stroke; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
Raising the safety bar--the FDA's coxib meeting. The New England journal of medicine, 2005, Mar-31, Volume: 352, Issue:13 Topics: Advertising; Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Drug Labeling; Humans; Isoxazoles; Lactones; Product Surveillance, Postmarketing; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra). CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2005, May-10, Volume: 172, Issue:10 Topics: Canada; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Contraindications; Cyclooxygenase Inhibitors; Decision Making; Drug Approval; Humans; Isoxazoles; Product Surveillance, Postmarketing; Pyrazoles; Risk Factors; Sulfonamides; United States; United States Food and Drug Administration	2005
FDA ponders future of NSAIDs: Pfizer reluctantly withdraws Bextra. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2005, May-15, Volume: 62, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Drug Industry; Guidelines as Topic; Humans; Isoxazoles; Sulfonamides; United States; United States Food and Drug Administration	2005
[Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions]. Zeitschrift fur Rheumatologie, 2005, Volume: 64, Issue:4 Topics: Antirheumatic Agents; Cardiovascular Diseases; Consumer Product Safety; Cyclooxygenase Inhibitors; Drug Approval; Germany; Humans; Isoxazoles; Lactones; Practice Guidelines as Topic; Practice Patterns, Physicians'; Rheumatic Diseases; Sulfonamides; Sulfones	2005
Rescuing COX-2 inhibitors from the waste bin. Journal of the National Cancer Institute, 2005, Jun-01, Volume: 97, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Endothelial Cells; Humans; Isoxazoles; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A	2005
Valdecoxib withdrawal leaves pain relief treatment gap. Gastroenterology, 2005, Volume: 128, Issue:7 Topics: Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Decision Making; Drug Industry; Humans; Isoxazoles; Pain; Public Policy; Risk Factors; Sulfonamides; United States; United States Food and Drug Administration	2005
How celecoxib could be safer, how valdecoxib might have been. The Annals of pharmacotherapy, 2005, Volume: 39, Issue:9 Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Industry; Humans; Isoxazoles; Pyrazoles; Risk Assessment; Sulfonamides; United States; United States Food and Drug Administration	2005
Lessons to learn from the COX-2 saga. Yes, FDA reforms are needed. And marketing distorts how medications are used. But one moral to the story is that all drugs have risks. Harvard health letter, 2005, Volume: 30, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug-Related Side Effects and Adverse Reactions; Humans; Isoxazoles; Lactones; Marketing of Health Services; Naproxen; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen. Harvard heart letter : from Harvard Medical School, 2006, Volume: 17, Issue:2 Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Isoxazoles; Lactones; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones	2006
Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction. Circulation, 2007, Jan-23, Volume: 115, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Lactones; Myocardial Infarction; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Factors; Sulfonamides; Sulfones; Ventricular Remodeling	2007
Coxibs: can this class of drugs survive? Vascular health and risk management, 2005, Volume: 1, Issue:1 Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Evidence-Based Medicine; Half-Life; Humans; Isoxazoles; Lactones; Patient Selection; Pyrazoles; Pyridines; Sulfonamides; Sulfones	2005